"Anxiety medication use has surged, driven by a complex interplay of societal stressors, increased accessibility, and evolving mental health discourse, sparking debate about efficacy and potential harms."
The landscape of mental health treatment in the United States is undergoing a significant shift, marked by a substantial increase in the prescription and use of anxiety medications. This trend, particularly pronounced since the COVID-19 pandemic, has brought to the forefront critical discussions regarding the effectiveness, safety, and societal drivers behind this widespread reliance on pharmacological solutions for anxiety. While these medications offer relief to millions, concerns are being raised by some, including high-profile government officials, about their long-term impact and the potential for over-prescription.
A Nation Grapples with Anxiety: Statistics Reveal a Growing Trend
The data paints a clear picture: a growing proportion of American adults are turning to anxiety medications. According to recent survey data from the Centers for Disease Control and Prevention (CDC), the percentage of adults in the U.S. who took anxiety medication rose from 11.7% in 2019 to 14.3% in 2024. This surge represents an additional 8 million individuals, bringing the total to approximately 38 million Americans. The most significant increases were observed among younger adults, college graduates, and those identifying as LGBTQ+. This upward trajectory suggests that the pressures and uncertainties of modern life, exacerbated by recent global events, are taking a profound toll on the nation’s mental well-being.
The personal stories behind these statistics underscore the profound impact anxiety can have. Sadia Zapp, a 40-year-old communications director in New York, experienced this firsthand after undergoing rigorous treatment for breast cancer. The ordeal left her with a deep-seated anxiety, where even minor physical discomforts triggered fears of dire consequences. "Every little ache, like a knee pain, would make me think: this is the end of the road for me," she recounted. Seeking relief, Zapp began taking Lexapro, a selective serotonin reuptake inhibitor (SSRI) that boosts serotonin levels. She describes its impact as transformative: "I love it. It’s been excellent. It has really helped me manage it."
SSRI’s: A Double-Edged Sword in Mental Health Treatment
The widespread adoption of medications like Prozac, Zoloft, and Lexapro, all SSRIs, has not been without controversy. While psychiatrists and researchers generally regard these drugs as first-line treatments for various anxiety disorders, including generalized anxiety disorder and panic disorder, citing their proven safety for long-term use, a vocal opposition has emerged. Proponents of the "Make America Healthy Again" (MAHA) movement argue that SSRIs are detrimental and potentially addictive.
Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services (HHS), has been a prominent critic. During his confirmation hearing, he controversially stated that he knew individuals, including family members, who found it harder to discontinue SSRIs than heroin. More recently, he has suggested his agency is investigating a potential link between SSRIs and other psychiatric medications and violent behaviors, such as school shootings. Similarly, Marty Makary, a commissioner on the Food and Drug Administration (FDA), has raised concerns about the potential for ISRS use in pregnant women to lead to adverse birth outcomes.
These critiques stand in contrast to the clinical consensus. Common side effects of SSRIs, such as stomach upset, difficulty concentrating, and fatigue, are often mild and manageable for many. Some individuals may experience a reduced libido or other sexual side effects, but these are not universal. Patrick Kelly, president of the Southern California Psychiatric Society, asserts that many of the claims against SSRIs are unsubstantiated. "The statements about SSRIs simply weren’t based on any sort of evidence or fact," Kelly stated regarding Kennedy’s comments. He further emphasized that for a significant number of patients, the benefits of treating chronic anxiety far outweigh the potential side effects.
Evidence supports the efficacy of SSRIs. A recent study indicated that over half of individuals with generalized anxiety disorder taking an SSRI experienced at least a 50% reduction in their anxiety symptoms. While approximately 1 in 12 individuals discontinued the medication due to side effects, the majority found sustained relief. Emily Wood, a psychiatrist practicing in Los Angeles, highlights that when prescribed appropriately and complemented by therapy, SSRIs can be highly effective.
MAHA’s Alternative Approach: Diet, Exercise, and Lifestyle
The MAHA movement attributes the rise in anxiety and other mental health challenges not to chemical imbalances, but to poor dietary choices and sedentary lifestyles. Their proposed solutions focus on reducing the consumption of ultra-processed foods, which recent studies have linked to depression and anxiety, and minimizing screen time in favor of increased physical activity. Psychiatrists generally endorse a healthy diet and exercise as complementary therapies for anxiety and depression. Wood suggests that individuals who can manage anxiety without medication should also explore talk therapy, noting that anxiety disorders respond particularly well to cognitive-behavioral therapy. The use of mental health counseling services in the U.S. has also seen an increase, with teletherapy gaining significant traction.
However, the narrative surrounding medication, particularly during pregnancy, is fraught with complexity. While studies suggest that the risks associated with SSRI use during pregnancy are low for both mother and baby, untreated maternal depression carries significant risks for both. Wood argues that recent government pronouncements questioning SSRI use in pregnancy could be causing genuine harm to expectant mothers by creating undue fear and potentially deterring them from essential treatment.
The issue of discontinuation syndrome, where individuals experience withdrawal-like symptoms such as nausea or insomnia upon abruptly stopping antidepressants, is also a point of contention. Kelly clarifies that this is distinct from addiction, a concept he believes is misapplied to SSRIs, a stance supported by research. Addiction is more typically associated with benzodiazepines like Xanax, often used as a second-line treatment for anxiety. These controlled substances carry a risk of dependence and can heighten the danger of opioid overdose when taken concurrently. Kennedy has also criticized the over-reliance on benzodiazepines, which, while effective for acute anxiety, require careful management and are not suitable for long-term use due to their potential for dependence.
A growing number of individuals are also using beta-blockers, such as propranolol, off-label for anxiety. While not FDA-approved for anxiety disorders, they can help mitigate physical symptoms like rapid heart rate before stressful events. Wood notes that beta-blockers, which can cause dizziness and fatigue, do not lead to addiction and are safe for reducing autonomic nervous system activation.
Societal Shifts Fueling the Anxiety Medication Surge
Several theories attempt to explain the burgeoning use of anxiety medications. Experts point to increased social media engagement, greater social isolation, and heightened economic uncertainty as contributing factors. The relative ease of obtaining prescriptions further facilitates this trend. Many individuals receive SSRI and benzodiazepine prescriptions from their primary care physicians or after brief telehealth consultations.
The open discussion of mental health challenges by social media influencers has played a role in destigmatizing these issues, particularly among young people, encouraging them to seek help. A recent Pew Research Center study indicated that approximately one-third of teenagers use social media to find information about mental health. However, this increased accessibility, coupled with a tendency for self-diagnosis based on online information, can be problematic. Online searches for medications like Xanax can yield sponsored ads promising same-day treatment, often without guaranteeing a prescription, highlighting the risks of unregulated access.
Young adults, aged 18 to 34, are driving a significant portion of the increase in anxiety medication use, with their usage rate rising from 8.8% in 2019 to 14.6% in 2024, according to CDC data. This contrasts with a more stable rate among older adults. The COVID-19 pandemic and subsequent lockdowns amplified stress levels, particularly for this demographic.
Data consistently shows that women are more likely to take anxiety medications than men. Jason Schnittker, Chair and Professor of Sociology at the University of Pennsylvania, suggests this disparity stems from a combination of factors: women may experience higher rates of anxiety, are more inclined to report their feelings, and are more readily identified as experiencing anxiety by healthcare providers. Broader societal trends also contribute; Schnittker notes that anxiety has become more prevalent across successive generations throughout the 20th and 21st centuries. Factors such as widening income inequality, leading to pressure to improve economic standing, increased social isolation, and a decline in trust among individuals, all contribute to a pervasive sense of unease.
For Sadia Zapp, the journey to stability involved a combination of medication and therapy. It took several months for the Lexapro to show clear results, but when it did, she experienced a noticeable reduction in mental clutter, allowing for improved focus. While she continues with therapy, her chronic anxiety is now managed primarily through medication, enabling her to re-engage with her daily life in a productive, rather than anxiety-ridden, manner. The ongoing evolution of understanding and treating anxiety reflects a complex interplay of individual experiences, medical advancements, and the ever-changing dynamics of society.